Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 20496342)

1.

Drug Class Review: Fixed Dose Combination Drug Products for the Treatment of Type 2 Diabetes and Hyperlipidemia: Final Report [Internet].

McDonagh M, Peterson K, Thakurta SG, Dana T.

Portland (OR): Oregon Health & Science University; 2007 Oct.

2.

Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-Release Fixed-Dose Combination Tablets Relative to Single-Component Dapagliflozin and Metformin Extended-Release Tablets in Healthy Subjects.

Chang M, Liu X, Cui D, Liang D, LaCreta F, Griffen SC, Lubin S, Quamina-Edghill D, Boulton DW.

Clin Ther. 2015 Jun 2. pii: S0149-2918(15)00291-X. doi: 10.1016/j.clinthera.2015.05.004. [Epub ahead of print]

PMID:
26048185
3.

Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.

Seong JM, Choi NK, Shin JY, Chang Y, Kim YJ, Lee J, Kim JY, Park BJ.

PLoS One. 2015 May 20;10(5):e0124287. doi: 10.1371/journal.pone.0124287. eCollection 2015.

4.

Ezetimibe plus simvastatin for the treatment of hypercholesterolemia.

Gryn SE, Hegele RA.

Expert Opin Pharmacother. 2015 Jun;16(8):1255-62. doi: 10.1517/14656566.2015.1041504. Epub 2015 Apr 28.

PMID:
25920750
5.

Oral and Injectable (Non-insulin) Pharmacological Agents for Type 2 Diabetes.

Evans JL, Balkan B, Rushakoff RJ.

In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2013 Dec 12.

6.

The Combination of DPP-4 Inhibitors Versus Sulfonylureas with Metformin After Failure of First-line Treatment in the Risk for Major Cardiovascular Events and Death.

Yu OH, Yin H, Azoulay L.

Can J Diabetes. 2015 Apr 1. pii: S1499-2671(15)00328-7. doi: 10.1016/j.jcjd.2015.02.002. [Epub ahead of print]

PMID:
25840943
7.

Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes.

Goldman-Levine JD.

Ann Pharmacother. 2015 Jun;49(6):688-699. Epub 2015 Mar 13. Review.

PMID:
25770115
8.

A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.

Park SI, Lee H, Oh J, Lim KS, Jang IJ, Kim JA, Jung JH, Yu KS.

Drug Des Devel Ther. 2015 Feb 4;9:729-36. doi: 10.2147/DDDT.S75980. eCollection 2015.

9.

Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes.

Haak T.

Clin Med Insights Endocrinol Diabetes. 2015 Jan 4;8:1-6. doi: 10.4137/CMED.S10360. eCollection 2015. Review.

10.

[Low persistence of simvastatin and ezetimibe fixed combination in the lipid lowering therapy].

Simonyi G, Ferenci T.

Orv Hetil. 2015 Jan 25;156(4):141-5. doi: 10.1556/OH.2015.30085. Hungarian.

PMID:
25597318
11.

Fixed-dose combination therapy in type 2 diabetes mellitus.

Blonde L, San Juan ZT, Bolton P.

Endocr Pract. 2014 Dec;20(12):1322-32. doi: 10.4158/EP14259.RA.

PMID:
25370323
12.

Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.

Berkowitz SA, Krumme AA, Avorn J, Brennan T, Matlin OS, Spettell CM, Pezalla EJ, Brill G, Shrank WH, Choudhry NK.

JAMA Intern Med. 2014 Dec;174(12):1955-62. doi: 10.1001/jamainternmed.2014.5294.

PMID:
25347323
13.

Linagliptin: an update of its use in patients with type 2 diabetes mellitus.

McKeage K.

Drugs. 2014 Oct;74(16):1927-46. doi: 10.1007/s40265-014-0308-3.

PMID:
25297911
14.

Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.

Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, Parag V, Harwood M, Doughty RN, Arroll B, Milne RJ, Bramley D, Bryant L, Jackson R, Rodgers A.

BMJ. 2014 May 27;348:g3318. doi: 10.1136/bmj.g3318.

15.

Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.

Mogensen UM, Andersson C, Fosbøl EL, Schramm TK, Vaag A, Scheller NM, Torp-Pedersen C, Gislason G, Køber L.

Diabetes Obes Metab. 2014 Oct;16(10):1001-8. doi: 10.1111/dom.12314. Epub 2014 Jun 9.

PMID:
24827939
16.

The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.

Dai X, Wang H, Jing Z, Fu P.

Curr Med Res Opin. 2014 Sep;30(9):1777-86. doi: 10.1185/03007995.2014.921608. Epub 2014 May 28. Review.

PMID:
24805140
18.

Vildagliptin: a review of its use in type 2 diabetes mellitus.

Keating GM.

Drugs. 2014 Apr;74(5):587-610. doi: 10.1007/s40265-014-0199-3. Review.

PMID:
24638989
19.

Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.

Zhou YT, Yu LS, Zeng S, Huang YW, Xu HM, Zhou Q.

Ther Clin Risk Manag. 2014;10:17-26. doi: 10.2147/TCRM.S55512. Epub 2013 Dec 20. Review.

20.

Second- and Third-Line Pharmacotherapy for Type 2 Diabetes: Update [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Jul.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk